Skip to main content
Search form
Home
About Heron
Company Overview
IITs, Grants, Sponsorships, and Contributions
Management
Board of Directors
Compliance
Contact Us
Careers
Our Focus
Our Mission
Our Technologies
About the 505(
b
)(2) Regulatory Pathway
Product Portfolio
Pipeline
SUSTOL
®
CINVANTI
®
HTX-011 (ZYNRELEF™)
HTX-034
Patient/Investigator Resources
About Chemotherapy-Induced Nausea and Vomiting (CINV)
About Pain Management
Scientific Posters and Presentations
Publications
Investor Resources
Investor Resources Home
News, Events and Presentations
News Releases
Events and Webcasts
Corporate Presentations
SEC Filings
Stock Information
Stock Quote
Stock Chart
Analyst Coverage
Corporate Governance
Board of Directors
Committee Composition
Corporate Governance Documents
Information Request
Material Request
E-mail Alerts
RSS Feeds
Developing Best-in-Class Medicine. Improving Lives.
Recent News
January 21, 2021
|
Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery
January 11, 2021
|
Heron Therapeutics Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program
November 13, 2020
|
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain
More News
Quick Links
Corporate Presentation
Pipeline
Scientific Posters and Presentations
